Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diuretics MINNEAPOLIS, Feb. 06, 2024 (GLOBE ...
NEWTON, Mass. and SHEFAYIM, Israel, Dec. 8, 2025 /PRNewswire/ -- AQUAPASS, a medical technology company pioneering non-invasive fluid management solutions, has received marketing approval for the ...
The Finkelstein-Schoenfeld Method of Win Ratios Analysis Provides New Insights Into Superiority of Ultrafiltration over Diuretics in Treating Fluid Overloaded Heart Failure Patients Resistant to ...
, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Ghent, Belgium – 14 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA (the “Company” or “Sequana Medical” ), a pioneer in the treatment of drug-resistant ...
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NUWE) (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is ...
Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...
Nuwellis Inc (NASDAQ:NUWE) saw its stock decline by 10% after announcing it will discontinue its REVERSE-HF clinical trial, which was assessing the effectiveness of ultrafiltration versus intravenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback